Chromium (n = 20) Placebo (n = 19) Age (y) 47.6 ± 1.7 47.3 ± 1.7 Gender (male/female) 13/7 13/6 Race (Caucasian/African American) 7/13 6/13 BMI (kg/m2) 28.2 ± 0.8 26.9 ± 1 CD4 (count/mm3) 676 ± 78 686 ± 61 Duration of HIV Infection (y) 16.8 ± 1.4 16.3 ± 1.0 LipodystrophyScorea 2.2 ± 0.41 2.1 ± 0.41 Smokers (%) 17/20 (85%) 18/19 (94.7%) Viral Load (copies/mL) 188 ± 67 268 ± 210 Subjects with fasting glucose ≥ 6.1 mmol/L (%) 4/20 (20%) 3/19 (15.8%) Subjects with triglycerides ≥ 2 mmol/L (%) 6/20 (30%) 7/18 (38.9%) Subjects with total cholesterol ≥ 5.5 mmol/L (%) 2/20 (10%) 1/18 (5.6%) Subjects with HDL-cholesterol ≤ 0.9 mmol/L (%) 7/20 (35%) 6/18 (33.3%) aLipodystrophyscore based physician assessment (scale 0-18)

Medications Chromium (n = 20) Placebo (n = 19) Lipid Lowering 5/20 (25%) 1/19 (5.3%) Cardiovascular 5/20 (25%) 3/19 (15.8%) Antidepressant 5/20 (25%) 6/19 (31.6%) Nucleoside Reverse Transcriptase Inhibitors 15/20 (75%) 13/19 (68.4%) Non- Nucleoside Reverse Transcriptase Inhibitors 4/20 (20%) 2/19 (10.5%) Protease Inhibitors 11/20 (55%) 12/19 (63.2%) Fusion Inhibitors 1/20 (5%) 0/19 (0%) Atripla (NNRTI + NRTI + NRTI) 4/20 (20%) 3/19 (15.8%) Results are reported as Mean ± SEM or % of subjects. Chi-square and un-paired Student t-test were used to compare the two groups and there were no significant differences between the groups. NNRTI is non-nucleoside reverse transcriptase inhibitors; NRTI is nucleoside reverse transcriptase inhibitors.

Table 1: Subject characteristics and medications.

Goto home»